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Abstract
Objective To quantify the contributions of prevention and treatment to
the trends in mortality due to coronary heart disease in Scotland.
DesignRetrospective analysis using IMPACTSEC, a previously validated
policy model, to apportion the recent decline in coronary heart disease
mortality to changes in major cardiovascular risk factors and to increases
in more than 40 treatments in nine non-overlapping groups of patients.
Setting Scotland.
Participants All adults aged 25 years or over, stratified by sex, age
group, and fifths of Scottish Index of Multiple Deprivation.
Main outcome measure Deaths prevented or postponed.
Results 5770 fewer deaths from coronary heart disease occurred in
2010 than would be expected if the 2000 mortality rates had persisted
(8042 rather than 13 813). This reflected a 43% fall in coronary heart
disease mortality rates (from 262 to 148 deaths per 100 000). Improved
treatments accounted for approximately 43% (95% confidence interval
33% to 61%) of the fall in mortality, and this benefit was evenly distributed
across deprivation fifths. Notable treatment contributions came from
primary prevention for hypercholesterolaemia (13%), secondary
prevention drugs (11%), and chronic angina treatments (7%). Risk factor
improvements accounted for approximately 39% (28% to 49%) of the
fall in mortality (44% in the most deprived fifth compared with only 36%
in the most affluent fifth). Reductions in systolic blood pressure
contributed more than one third (37%) of the decline in mortality, with
no socioeconomic patterning. Smaller contributions came from falls in
total cholesterol (9%), smoking (4%), and inactivity (2%). However,
increases in obesity and diabetes offset some of these benefits,
potentially increasing mortality by 4% and 8% respectively. Diabetes
showed strong socioeconomic patterning (12% increase in the most
deprived fifth compared with 5% for the most affluent fifth).
Conclusions Increases in medical treatments accounted for almost half
of the large recent decline in mortality due to coronary heart disease in
Scotland. Furthermore, the Scottish National Health Service seems to
have delivered these benefits equitably. However, the substantial
contributions from population falls in blood pressure and other risk factors
were diminished by adverse trends in obesity and diabetes. Additional
population-wide interventions are urgently needed to reduce coronary
heart disease mortality and inequalities in future decades.
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Introduction
Coronary heart disease (CHD) remains the largest cause of death
in Scotland, as elsewhere in Europe, the United States, and
Australasia. Scotland has one of the highest CHD mortality
rates in western Europe, accounting for more than 8000 deaths
in 2009. Furthermore, CHD is a major cause of premature
mortality (aged <75 years). The burden of disease is substantial,
and the estimated annual cost to the National Health Service
(NHS) in Scotland exceeds £3bn (€3.7bn; $5bn).1 CHD rates
have fallen dramatically since the 1970s; age adjusted mortality
rates for men dropped from 460 per 100 000 in 1979 to 136 per
100 000 in 2010, and rates for women dropped from 208 to 64
per 100 000.2 Studies in the United Kingdom, Europe, United
States, and New Zealand have suggested that 45-75% of the
substantial falls in deaths from CHD can be attributed to
population-wide decreases inmajor risk factors such as smoking,
blood pressure, and cholesterol.3-7 The remaining 25-55% can
apparently be explained by use of cardiological treatments such
as thrombolysis, aspirin, angiotensin converting enzyme
inhibitors, statins, and coronary artery bypass graft surgery.8
In Scotland, and elsewhere, evidence shows strong and persistent
socioeconomic inequalities in CHD incidence and mortality.9 10
O’Flaherty et al reported that premature mortality was up to
five times higher in the most deprived fifth compared with the
most affluent. Worryingly, mortality trends in younger men and
women seemed to have flattened recently, particularly in the
two most deprived fifths.9 The IMPACT model has been
developed to help to explain the decline in CHD deaths by
quantifying the contributions of temporal changes in exposure
to risk factors and uptake of treatments.11 The model has been
previously validated and used to explain such falls in mortality
in more than 20 countries including Scotland, New Zealand,
Finland, England, and the United States.3-7 Since 2009, themodel
has been further developed as IMPACTSEC. This permits
quantification of trends in CHD mortality, treatment uptakes,
and risk factors in socioeconomic fifths.12
Recent socioeconomic trends inmany cardiovascular risk factors
in Scotland have been unfavourable. For example, between 1995
and 2008 relative inequalities in blood pressure levels persisted
while inequalities in the prevalence of smoking and diabetes
increased in both men and women.13 What effect such trends
have had on socioeconomic trends in CHDmortality is unclear.
Against this background, we aimed to quantify the decline in
CHD mortality between 2000 and 2010 in Scotland and then
use the IMPACTSEC model to apportion this mortality decline
to treatments and changes in risk factors across socioeconomic
fifths.
Methods
IMPACTSEC model
The IMPACTCHDmortalitymodel is an epidemiologicalmodel
originally developed to explore the contribution of modern
cardiovascular treatment and changes in risk factors to the
decline in CHDmortality in Scotland between 1975 and 1994.3 4
This deterministic, cell based model integrates data from many
sources on patient numbers, treatment uptake, treatment
effectiveness, risk factor trends, and consequent mortality
effects. Using this information, the deaths prevented or
postponed between two specified time points can be calculated.
The proportion of the decline in CHD mortality over a certain
time period can then be attributed to changes in risk factors and
to specific treatments.
The model considers a comprehensive range of risk factors,
CHD categories, and treatments. In brief, the model includes
the population risk factors smoking, cholesterol, blood pressure,
obesity, diabetes, and physical activity. It also includes nine
mutually exclusive groups of patients: ST elevation myocardial
infarction, non-ST elevation acute coronary syndrome,
secondary prevention after myocardial infarction, secondary
prevention after revascularisation, chronic stable coronary artery
disease, patients with severe heart failure requiring at least one
admission to hospital, heart failure patients treated only in the
community, and two primary pharmacological prevention groups
of patients receiving antihypertensive drugs or statins.
The model has been further developed to partition into fifths
the socioeconomic components concealed within the overall
decline in CHD mortality and within the specific contributions
of improved treatments and changes in population risk factors.
The IMPACTSEC model can be used to synthesise data by fifths
of area deprivation from a range of databases (including
population, mortality, case fatality, health surveys, hospital
admissions, hospital prescribing, and community prescribing).
The flexibility of the IMPACTSEC model also allowed
stratification of results by sex; however, we did no formal tests
to explore possible disparities by sex. Further details for the
IMPACT and the IMPACTSEC models are described below and
in the summary appendix and technical appendix, as well as in
previous publications.11 12
Data sources
We sourced data relating to the Scottish population. We
investigated all possible sources and selected the most up to
date and representative dataset. Population estimates and CHD
death counts (ICD10 (international classification of diseases,
10th revision) codes I10-I25) for 2000 and for 2010 by 10 year
age bands (25-34 to ≥85 years), sex, and deprivation fifth came
from National Records of Scotland (www.nrscotland.gov.uk/).
Emergency admissions and surgical interventions for acute
myocardial infarction and unstable angina, as well as admissions
for heart failure, came from the linked Scottish Morbidity
Record (SMR01) and death record dataset provided by
Information Services Division Scotland (www.isdscotland.org/
). Primary Care Clinical Informatics Unit, University of
Aberdeen (www.abdn.ac.uk/pcciu/index.htm), provided
information on treatment uptake in community based patients.
Data on trends in risk factors came from the Scottish Health
Surveys.14 15 16 17 Rehabilitation data came from Information
Services Division Scotland. Treatment uptake data for heart
failure in hospital came from the Healthcare Improvement
Scotland audit (www.healthcareimprovementscotland.org).We
substituted English data from theMyocardial IschaemiaNational
Audit Project (MINAP) for uptake of acute coronary syndrome
treatment in hospital.12 HeartStart (Scotland) provided
community cardiopulmonary resuscitation data for ST elevation
myocardial infarction patients.18
Socioeconomic deprivation
We used the Scottish Index of Multiple Deprivation 2009v2 as
a measure of area level deprivation.19 This identifies small
concentrations of deprivation across Scotland by using data
from various sources from around 2007-08. It is based on the
stable and consistent small area geography called data zones,
of which there are 6505 in Scotland (average population 798
(range 0-7061) people) ranked from most deprived (1) to least
deprived (6505). The overall rankings are made up of seven
individual domains: current income, employment, health,
education, housing, access to services, and crime. On the basis
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of their postcode of residence, the data providers allocated
patients treated in hospital or in the community to the
corresponding deprivation fifth (to protect patients’ anonymity).
Survey respondents and deaths were matched to deprivation
fifths in a similar manner. We could not obtain data from the
Primary Care Clinical Informatics Unit stratified by people’s
Scottish Index of Multiple Deprivation area of residence. We
therefore substituted this by using the 2001 Carstairs index of
deprivation applied to the area of residence.20 This applied to
patient numbers for chronic angina and heart failure in the
community, as well as uptake of therapeutic drugs for all the
community groups. We used a χ2 test for linear trend across
deprivation fifths to assess socioeconomic gradients associated
with the proportion of CHD deaths explained by the model.
Deaths prevented or postponed
We calculated the number of CHD deaths expected in 2010 by
indirect standardisation, multiplying the age, sex, and Scottish
Index ofMultiple Deprivation fifth specific mortality rates from
CHD in 2000 by the relevant population counts for 2010.
Summing over all strata then yielded the expected number of
deaths. The difference between the number of expected and
observed deaths then represented the fall in mortality, the total
number of CHD deaths prevented or postponed to be explained
by the combined changes in risk factor levels and treatment
uptake between 2000 and 2010. If the model did not fully
explain all deaths prevented or postponed in each fifth, we
assumed any shortfalls to reflect unmeasured risk factors or
imprecision in the model’s parameters.
Mortality reductions attributable to treatment
uptake
We specified relevant treatments for each of the nine mutually
exclusive patient groups. These included acute myocardial
infarction (cardiopulmonary resuscitation, thrombolysis,
angioplasty, aspirin, β blockers, and angiotensin converting
enzyme inhibitors); secondary prevention following acute
myocardial infarction and, separately, following coronary artery
bypass graft surgery or angioplasty (aspirin, β blockers,
angiotensin converting enzyme inhibitors, statins, warfarin, and
rehabilitation); non-ST elevation myocardial infarction/acute
coronary syndrome (aspirin, heparin, platelet glycoprotein
IIB/IIIA inhibitors, and clopidogrel); chronic angina (coronary
artery bypass graft surgery, angioplasty, aspirin, statins); and
heart failure (angiotensin converting enzyme inhibitors, β
blockers, spironolactone, aspirin, statins).
To avoid double counting of patients, we used linked individual
data where possible; where this was not possible, we constructed
distinct, non-overlapping CHD patient subgroups (see technical
appendix). Numbers of patients eligible for each treatment,
uptake of treatment, one year case fatality rates, and relative
risk reduction due to treatment (all stratified by age, sex, patient
subgroup, and deprivation fifth) came from relevant data sources
as specified. As all treatments were in use in 2000, we calculated
the net benefit of medical intervention in 2010 by subtracting
the expected number of deaths prevented if the uptake rates in
2000 remained constant from the estimated number of deaths
prevented calculated using the 2010 uptake rates (see technical
appendix).
Mortality reductions attributable to risk factor
changes
We included six major cardiovascular risk factors in the model:
the behavioural markers of smoking, physical inactivity, and
bodymass index and the physiological markers of systolic blood
pressure, total serum cholesterol, and diagnosed diabetes. We
calculated the absolute change in each risk factor between 2000
and 2010 by using generalised linear models with normal
distribution and identity link for the continuous risk factors and
generalised linear models with a binomial distribution and a
logit link function for categorical variables (technical appendix,
table C).
We estimated the mortality benefits of an absolute change in
each risk factor between 2000 and 2010 by using a regression
based approach for factors measured on a continuous scale (such
as total blood cholesterol), using sex and age specific
independent regression coefficients of mortality benefit for a
unit change in mean risk factor obtained from published
multivariate analyses (technical appendix, table I). For binary
variables (such as smoking), we used a population attributable
risk fraction approach using sex and age specific relative risks
from the most recent meta-analyses and population cohort
studies (technical appendix, table J). We jointly estimated
mortality benefits of changes in risk factors by using the
cumulative risk reduction approach, rather than simple addition
(technical appendix, section 1.3).
We assumed that no further synergy existed between the
treatment and risk factor components of the model.We assumed
lag times between the change in cardiovascular risk factor levels
and change in CHD mortality rates to be relatively rapid,21 so
we did not specifically model them.
Uncertainty analysis
We calculated 95% uncertainty intervals around the model
output (that is, deaths prevented or postponed ) by using Monte
Carlo simulation, much as in health economic evaluation
studies.22 This calculation involved replacing all fixed input
parameters used in the model by appropriate probability
distributions and repeatedly recalculating the model output with
values sampled from the defined input distributions. We used
the Excel add-in Ersatz software (www.epigear.com) to do 1000
runs to determine the 95% uncertainty intervals of the deaths
prevented or postponed (2.5th and 97.5th centile values
corresponding to the lower and upper limits) (see technical
appendix).
Results
The age standardised CHDmortality rate in adults aged 25 years
and over fell by 43% between 2000 and 2010, from 262 to 148
deaths per 100 000 population (table 1⇓). Mortality rates in
2000 in the most affluent fifth were 181 per 100 000 population
compared with 349 per 100 000 in the most deprived fifth.
Furthermore, the pace of fall differed significantly; the most
affluent fifth decreased by 5.8% a year compared with 4.6% in
the most deprived fifth. Thus absolute inequalities narrowed
over the 10 year time period, whereas relative inequalities
widened.
In total, 5770 fewer CHD deaths occurred in 2010 than would
have been expected had the 2000 mortality rates persisted; this
figure represents the total deaths prevented or postponed. One
thousand two hundred and thirty deaths were prevented or
postponed in the most deprived fifth, compared with 905 in the
most affluent fifth (reflecting the higher initial burden of disease;
table 1⇓). When examining the deaths prevented or postponed
as a percentage of expected deaths (percentage of deaths
prevented or postponed), we observed a significant inequality
gradient with a decrease in mortality of 44% in the most affluent
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fifth and 38% in the most deprived fifth; this gradient was also
evident with stratification by sex.
As a result of improvements in the uptake of medical and
surgical treatments, 2480 fewer deaths occurred. This accounted
for 43% (95% confidence interval 33% to 61%) of the fall in
total CHD mortality in Scotland (table 2⇓); minimal difference
existed in this proportion by sex (table 3⇓). No significant
socioeconomic gradient existed (46% in the most affluent fifth
and 44% in the most deprived fifth), and this was true for each
sex (table 3⇓). Population level changes in risk factors accounted
for approximately 2240 fewer deaths or 39% (29% to 49%) of
the fall (table 4⇓). These accounted for 36% of the deaths
prevented or postponed in the most affluent fifth, increasing to
44% in the most deprived fifth. Again, minimal difference
existed in these proportions by sex (table 3⇓). The model could
therefore explain only 82% of the overall fall in mortality (a
shortfall of some 1055 deaths) (tables 3⇓ and 4⇓). A
socioeconomic gradient was evident; 81% of deaths prevented
or postponed were explained in the most affluent fifth and 88%
in the most deprived fifth.
Increased treatments
The largest contribution to deaths prevented by increased uptake
of treatment came from statin treatment for hyperlipidaemia
(approximately 13% of the total mortality reduction), followed
by secondary prevention after myocardial infarction (9%) and
management of chronic stable coronary artery disease (7%)
(table 2⇓). Uptake rates of statins and angiotensin converting
enzyme inhibitors or angiotensin receptor blockers more than
doubled between 2000 and 2010 for secondary prevention and
the management of stable coronary artery disease (table 5⇓).
These two treatments together contributed to approximately
750 (13%) deaths prevented or postponed. Improved heart
failure treatments contributed approximately 265 (5%) deaths
prevented or postponed in community patients and 85 (2%)
fewer deaths in patients admitted to hospital. Only small
contributions to deaths prevented or postponed were made in
the hospital based patient groups of emergency admissions for
acute coronary syndromes (table 2⇓).
The improvements due to changes in treatment uptakes were
evenly distributed across deprivation fifths. The difference
between themost and least deprived fifths in terms of percentage
of deaths prevented or postponed was generally less than 1%
for each treatment group (table 3⇓).
Risk factor changes
The largest contribution from population level changes in risk
factors came from the 2 mm Hg fall in systolic blood pressure
in people not on antihypertensive drugs; this generated
approximately 2130 fewer deaths, representing 37% of the
mortality decrease (table 4⇓). In contrast, the benefits from
treatment of hypertension were fairly small, with some 155
(3%) deaths averted (table 2⇓). Socioeconomic gradients were
modest; however, population level systolic blood pressure
dropped during the 10 year period by 3.2 mmHg in women and
by only 0.9 mm Hg in men (table 6⇓).
The fall in cholesterol concentrations in the population not on
statin treatment accounted for approximately 510 deaths averted,
representing 9% of the total fall. In both absolute and relative
terms, the fall in deaths attributable to cholesterol reduction in
the general population was substantially higher in the most
deprived fifth (170 (14%) fewer deaths) than in the most affluent
fifth (43 (5%) fewer deaths). During the 10 year study period,
uptake of statin treatment increased substantially, from 3% of
eligible people in 2000 to 15% in 2010 (13% in the most affluent
fifth and 17% in the most deprived fifth) (table 5⇓). Cholesterol
lowering by statins thus accounted for approximately 770 (13%)
deaths averted, 15% in the most affluent fifth and 11% in the
most deprived fifth (table 2⇓).
Favourable trends in the behavioural risk factors made a modest
contribution to deaths prevented or postponed; the drop in
smoking rates contributed to approximately 210 fewer deaths
or 4% (table 4⇓). Smoking prevalence dropped by about 4% in
men and 5% in women over the 10 year time period. A
significant socioeconomic gradient was apparent, with
approximately 14 (2%) fewer deaths evident in the most affluent
fifth and some 75 (6%) fewer deaths in the most deprived fifth
(table 3⇓), reflecting larger declines in smoking prevalence.
Physical inactivity declined by approximately 7% in men and
6% in women (table 6⇓) and contributed to approximately 100
(2%) fewer deaths.
Adverse risk factor trends
The mortality gains from decreases in smoking and physical
inactivity were cancelled out by increases in obesity and
diabetes. Increases in body mass index contributed
approximately 235 (−4%) additional deaths and diabetes some
475 (−8%) additional deaths (table 4⇓). The additional deaths
from diabetes showed a significant socioeconomic gradient,
with 48 (−5%) more deaths in the most affluent fifth and 141
(−12%) in the most deprived fifth (table 3⇓). This reflected a
gradient in prevalence of diabetes which increased in men by
2% (1% in women) in the most affluent fifth and by 4% (3% in
women) in the most deprived fifth (table 6⇓). No significant
socioeconomic gradients were associated with body mass index
attributable deaths (tables 3⇓ and 4⇓).
Discussion
Coronary heart disease remains a top policy priority in Scotland.
CHD mortality fell by more than 40% between 2000 and 2010,
resulting in approximately 5770 fewer deaths. The largest
contributors to this decline were favourable population level
falls in blood pressure and serum cholesterol concentrations.
However, we found evidence of unfavourable trends in body
mass index and diabetes that threaten to reverse these trends.
The falls in mortality were steeper in the more affluent groups,
so relative inequalities remained fairly constant. These
differentials are likely to reflect inequalities in risk factor trends,
rather than in evidence based treatments (whichwere remarkably
equitable).
Reductions in cardiovascular risk factor levels explained
approximately two fifths of the fall in CHDmortality. The single
largest contribution came from secular falls in population blood
pressure. Furthermore, blood pressure falls were of a similar
magnitude across socioeconomic groups. This is consistent with
the encouraging population-wide reductions in dietary salt
consumption seen in Scotland and England.13 23 The greater fall
in blood pressure in women than in men resulted in a
correspondingly larger contribution to the CHD deaths
prevented. The underlying contributory factors therefore
represent a possible area for future investigation. As elsewhere,
themortality benefit from hypertension treatments was relatively
small.
Favourable trends in smoking and physical activity made only
a modest contribution to the falls in mortality. However, the
reductions in deaths due to smoking were greater in the deprived
groups, mirroring the larger declines in smoking prevalence.
This may reflect the benefits of smoke-free legislation
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introduced in Scotland in 2006.24 However, smoking remains
prevalent in deprived areas and substantial inequalities persist,
representing a government policy priority.25 26
Modest mortality benefits were also attributable to population
declines in cholesterol concentrations in people not on statin
treatment, again greater in deprived groups. These benefits may
reflect modest decreases in dietary saturated fat consumption
and increases in fruit and vegetable consumption. However, the
small benefits were notably less than for statin treatment.
Furthermore, the Scottish government’s dietary targets were
not met,27 leaving little room for complacency.
Adverse trends
Falls in major cardiovascular risk factor levels explained
approximately 40% of the fall in CHD mortality. However, the
net benefit was substantially reduced by increasing levels of
obesity and diabetes, which together increased mortality by
12% (>700 additional deaths). Increasing prevalence of diabetes
showed a strong socioeconomic gradient whereby surplus deaths
were almost three times higher in the most deprived group than
the most affluent. This represents a clarion call to policy
makers.28
Treatment contributions
Approximately 40% of the total fall in CHD mortality was
attributable to improvements in the uptake of treatments, notably
a doubling in drug use in the community. Medical interventions
in hospital settings made only a small additional contribution
because CHD incidence rates are declining with fewer patients
therefore being admitted to hospital with acute disease, treatment
uptakes were already high (hence with little margin for further
increases), and few new treatments were introduced during the
study period.
Although the CHDdisease burden showed strong socioeconomic
gradients, the improvements in mortality due to changes in
treatment uptake were fairly evenly distributed across
deprivation fifths. This is gratifying and suggests an equitable
delivery of CHD care by the Scottish NHS. Subjectively, sex
equality also existed in the delivery of care, although this
requires further formal investigation.
Comparison with England IMPACTSECmodel
Our analysis is only the second IMPACTSEC study to examine
socioeconomic trends in CHDmortality. It thus begs comparison
with the first, which modelled similar English data between
2000 and 2007.12
As expected, many similarities exist, including substantial and
persistent socioeconomic inequalities in CHD death rates and
smoking levels. Overall mortality falls were equally large, and
in both cases a third was attributable to changes in risk factors.
The biggest contribution to the fall in mortality was consistently
attributed to declines in population blood pressure (37% in
Scotland and 30% in England), partly reflecting reductions in
dietary salt. In both countries, worrying adverse trends in body
mass index and diabetes equated to substantial rises in coronary
mortality (12% in Scotland; 9% in England).
The Scottish model attributed approximately 40% of the total
fall in CHD mortality to improved uptakes of medical
treatments, compared with 50% in England. Importantly, both
models showed equitable reductions in mortality attributable to
treatments across socioeconomic groups, most likely reflecting
the uniform health service provision for CHD treatments.
Strengths and limitations
This is the first study to use local datasets to quantify detailed
contributions of changes in treatment and risk factors to falls
in coronary mortality within socioeconomic groups in Scotland.
It is only the second IMPACT study to examine socioeconomic
variations. Scotland benefits from having the only UKmorbidity
databases that routinely link all hospital admission information
with all mortality data. This should generate accurate estimates
of various patient groups, incidence, and case fatality stratified
by age, sex, and, where numbers are large enough, deprivation.
This minimised the assumptions that had to be made regarding
overlap between disease groups by ensuring that people could
be included in only one group. Some data were difficult to
access, perhaps reflecting insufficient resources to sustain
diverse audit projects.
Several limitations should also be acknowledged. Firstly, the
routine data used in this study permitted stratification by an area
based measure of deprivation, but not by individual person.
However, such small area indices offer reasonably effective
markers of personal social status.29
Secondly, mortality rates are dependent on population estimates.
Because population estimates from the 2011 census were not
yet available, the small area population estimates by data zone
needed for our Scottish Index ofMultiple Deprivation stratified
analysis were based on the 2000 census with populations rolled
forward to 2010.30 Clearly, small areas may change over time
with regards to population size, demographic characteristics,
and socioeconomic make-up, so estimates of mortality rates
may be less stable in 2010.
Thirdly, our model could not explain 18% of the overall decline
in CHD mortality; uncertainty analyses would suggest that this
figure could be as little as 1% or as much as 35%. Several
possible explanations exist for this shortfall. Firstly, risk factor
estimates obtained from the Scottish Health Survey may lack
precision owing to small numbers, compounded by self reporting
of smoking and inactivity levels and declining survey response
rates.31 Secondly, other risk factors such as psychosocial stress
and dietary consumption of fruit and vegetables, saturated fat,
or alcohol were omitted from our model. However, the effect
of these “upstream” factors should be partly quantified by trends
in “downstream” factors (blood pressure, cholesterol, bodymass
index, and diabetes).32 Furthermore, the consistent results from
the rigorous sensitivity analyses were reassuring.
Policy implications
The substantial decline in CHD mortality over the past decade
in Scotland can be attributed fairly equally to increasedmedical
treatments and to improvements in risk factors. However, the
potentially powerful reductions in smoking and cholesterol were
frustratingly small andwere completely negated by large adverse
trends in obesity and diabetes. Scotland’s past tobacco and
dietary policies deserve credit.25 26 However, more effective
public health policies exist elsewhere and have substantially
and equitably reduced the intake of saturated fats, trans fats,
salt, and sugars.28 33 34 Likewise, proposed standard packaging
legislation,26 if implemented, could lower smoking in all
socioeconomic groups and thus reduce CHD mortality across
Scotland.
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What is already known on this topic
In spite of recent falls in mortality, coronary heart disease (CHD) remains the largest cause of death in Scotland and generates strong
and persistent socioeconomic inequalities
Smoking prevalence in Scotland has fallen, but absolute levels remain high
Worryingly, other cardiovascular risk factors such as obesity and diabetes have recently increased
What this study adds
CHD mortality in Scotland fell by 43% between 2000 and 2010; the single largest contribution came from population level falls in blood
pressure
The contribution from improvements in smoking and cholesterol concentrations was frustratingly small and was completely negated by
increases in obesity and diabetes
The CHD burden showed strong socioeconomic gradients; however, the mortality reductions attributable to improved treatment uptakes
were evenly distributed across socioeconomic fifths, suggesting an equitable delivery of care by the Scottish NHS
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Tables
Table 1| Population, observed coronary heart disease deaths/age standardised rates for 2000 and 2010, and deaths prevented or postponed
(DPPs) in Scotland stratified by deprivation fifths; data presented for whole population as well as by sex
Scottish Index of Multiple Deprivation fifths
Scotland 5 (most deprived)4321 (most affluent)
All adults aged ≥25 years
Population:
719 658726 937705 803678 440685 1623 516 0002000
695 782736 790755 559761 624735 7893 685 5442010
Observed deaths:
3252292725631965155312 2602000
1989192015791417113780422010
Age standardised rates (per 100 000)*:
349 (337 to 361)283 (272 to 293)263 (253 to 274)215 (206 to 225)181 (171 to 190)262 (257 to 266)2000 (95% CI)
217 (207 to 227)177 (168 to 185)137 (130 to 144)120 (113 to 126)100 (94 to 106)148 (145 to 151)2010 (95% CI)
4.64.66.35.75.85.5Annual % fall
3218310729712476204213 813Expected deaths in 2010 (if 2000 rates had
persisted)
12301185139010609055770Deaths prevented or postponed
(expected−observed deaths)
38.238.246.942.844.341.8DPPs as % of expected deaths†
Men aged ≥25 years
Age standardised rates (per 100 000)*:
494 (471 to 518)393 (373 to 413)364 (344 to 383)293 (275 to 311)252 (235 to 270)363 (354 to 372)2000 (95% CI)
313 (295 to 332)253 (238 to 269)197 (184 to 210)169 (157 to 181)139 (128 to 150)210 (204 to 216)2010 (95% CI)
4.54.35.95.45.85.3Annual % fall
179916841653134811197603Expected deaths in 2010 (if 2000 rates had
persisted)
6656057455654953075Deaths prevented or postponed
(expected−observed deaths)
37.035.945.141.944.240.4DPPs as % of expected deaths‡
Women aged ≥25 years
Age standardised rates (per 100 000)*:
239 (226 to 252)201 (190 to 213)186 (175 to 197)155 (145 to 166)129 (119 to 139)185 (180 to 190)2000 (95% CI)
141 (131 to 151)118 (109 to 127)91 (83 to 98)81 (74 to 87)69 (63 to 76)99 (96 to 103)2010 (95% CI)
5.15.26.96.36.06.0Annual % fall
14191423131711289236210Expected deaths in 2010 (if 2000 rates had
persisted)
5655806454954102695Deaths prevented or postponed
(expected−observed deaths)
39.840.849.043.944.443.4DPPs as % of expected deaths§
DPPs have been rounded to nearest 5.
*Rates are standardised to European standard population aged ≥25 years by using direct standardisation.
†χ2 test for linear trend across deprivation fifths P<0.0001.
‡χ2 test for linear trend across deprivation fifths P<0.0001.
§χ2 test for linear trend across deprivation fifths P=0.002.
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Table 2| Coronary heart disease deaths prevented or postponed (DPPs) owing to changes in treatment uptake between 2000 and 2010 in
Scotland, stratified by deprivation fifth
Scottish Index of Multiple Deprivation fifthsProportion of total
DPPs—% (95%
AllTreatments by patient groups
5 (most
deprived432
1 (most
affluent)
uncertainty
interval*)
24232121191.9 (0.6 to 5.0)110ST elevation myocardial infarction†:
110100.02Community cardiopulmonary
resuscitation
000000.00Hospital cardiopulmonary
resuscitation‡
000000.00Thrombolysis‡
111110.14Aspirin
000000.00β blockers
000000.00ACE inhibitors/ARB
19191818161.690Primary percutaneous coronary
intervention
000000.00Coronary artery bypass graft surgery
232220.212Clopidogrel
20171516101.3 (0.7 to 2.4)80Non-ST elevation acute coronary
syndrome†:
000000.00Hospital cardiopulmonary
resuscitation‡
85401180.740Aspirin and heparin
000000.00Aspirin alone
00−0.1000.0−0.1Platelet glycoprotein IIB/IIIA inhibitors
000000.00Coronary artery bypass graft surgery
217210.17Percutaneous coronary intervention
115110.15ACE inhibitors/ARB
103110.03β blockers
5423550.423Clopidogrel
12511810787889.1 (7.4 to 11.2)525Secondary prevention post-myocardial
infarction†:
979470.635Aspirin
29272119192.0115β blockers
38342927262.7154ACE inhibitors/ARB
38383629272.9169Statins
334110.212Warfarin
898760.739Rehabilitation
26262720202.1 (1.4 to 3.0)120Secondary prevention
post-revascularisation†:
1−11−100.0−1Aspirin
786440.529β blockers
91011780.846ACE inhibitors/ARB
101011970.847Statins
−1−2−200−0.1−4Warfarin
0.00.00.00.00.00.00.0Rehabilitation (coronary artery bypass
graft)§
0.30.40.40.40.30.01.8Rehabilitation (percutaneous coronary
intervention)
75837974656.5 (4.6 to 9.1)375Chronic stable coronary artery disease:
−2001-3-0.1−4Coronary artery bypass graft surgery
1098980.843Aspirin
44495042413.9226Statins
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Table 2 (continued)
Scottish Index of Multiple Deprivation fifthsProportion of total
DPPs—% (95%
uncertainty
interval*)AllTreatments by patient groups
5 (most
deprived432
1 (most
affluent)
23252123191.9111ACE inhibitors
23191813121.5 (1.0 to 1.9)85Heart failure in hospital†:
555430.422ACE inhibitors
10109760.741β blockers
444320.318Spironolactone
301010.14Aspirin
76655839294.6 (3.6 to 6.0)265Heart failure (community)†:
10710530.635ACE inhibitors
65474229243.6207β blockers
−2116510.421Spironolactone
300−110.14Aspirin
33293033292.7 (0.7 to 6.0)155Hypertension treatment†
13813818317014013.3 (5.3 to 30.4)770Hyperlipidaemia treatment (statins)†
54051753847341243.0 (33.0 to 61.3)2480Total treatment†
DPPs for Scotland (subtotals and total treatment only) have been rounded to nearest 5 (column 2).
ACE=angiotensin converting enzyme; ARB=angiotensin receptor blockers.
*95% uncertainty interval corresponds to lower (2.5th centile) and upper (97.5th centile) limits of uncertainty analysis. These are shown to indicate range around
central estimate of per cent of DPPs explained. Intervals are provided only for nine treatment patient groups.
†Subtotals (in rows) for coronary heart disease patient groups.
‡Assuming no change in thrombolysis and cardiopulmonary resuscitation uptake in community between 2000 and 2010; their contribution to DPPs have therefore
been set to zero.
§No change in uptake between 2000 and 2010.
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Table 3| Coronary heart disease deaths prevented or postponed (DPPs) as percentage of total DPPs to be explained, stratified by deprivation
fifth; selected sex specific DPPs are provided
P value*
Scottish Index of Multiple Deprivation fifths
Scotland
Treatments by patient groups/risk
factors
5 (most
deprived)4321 (most affluent)
Treatments
0.962.01.91.52.02.11.9ST elevation myocardial infarction
0.381.61.41.11.51.11.3Non-ST elevation acute coronary
syndrome
0.2510.29.97.78.29.79.1Secondary prevention
post-myocardial infarction
0.902.12.22.01.92.22.1Secondary prevention
post-revascularisation
0.406.17.05.77.07.26.5Chronic stable coronary artery
disease
0.221.91.61.31.31.31.5Heart failure in hospital
0.00016.25.54.23.73.24.6Heart failure in community
0.322.72.52.13.13.22.7Hypertension treatment
<0.000111.211.713.116.115.413.3Hyperlipidaemia treatment (statins)
0.5343.943.638.644.745.543.0Total treatments—all†
0.4344.650.740.643.346.044.8Total treatments—men†
0.143.436.636.646.444.841.0Total treatments—women†
Risk factors
<0.00016.14.53.02.31.53.6Smoking
<0.0001−11.5−9.4−7.1−7.1−5.3−8.2Diabetes
0.062.31.91.51.51.31.7Physical inactivity
0.5137.240.333.237.337.536.9Systolic blood pressure, mm Hg
<0.000113.812.36.85.44.78.9Total cholesterol, mmol/L
0.49−4.3−4.5−3.6−4.1−3.9−4.1Body mass index
<0.000143.545.133.735.335.938.8Total risk factors†
0.0142.744.334.838.437.539.5Total risk factors—men†
<0.000144.645.932.431.833.837.9Total risk factors—women†
Deaths prevented or postponed
<0.000187.588.772.380.081.381.7DPPs explained by model—all†
<0.000187.395.175.481.783.684.3DPPs explained by model—men†
<0.000188.082.569.078.178.678.9DPPs explained by model—women†
—12.511.327.720.018.718.3DPPs not explained by model†
DPP counts
—1075105310068477364720DPPs explained by model†‡:
—5405175384734122480Due to treatment uptake‡
—5355354693743252240Due to risk factor change‡
—1541343852121691055DPPs unexplained by model†‡
—12301185139010609055770Total DPPs†‡
*χ2 test for linear trend.
†Subtotals (in rows).
‡Sex specific coronary heart disease DPPs as percentage of sex specific total DPPs to be explained (full sex stratified tables are available in technical appendix).
‡DPPs for Scotland (column 2) and total DPPs (last row) have been rounded to nearest 5.
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Table 4| Coronary heart disease deaths prevented or postponed (DPPs) owing to changes in risk factor prevalence between 2000 and 2010
in Scotland stratified by deprivation fifth
Scottish Index of Multiple Deprivation fifthsProportion of total DPPs—%
(95% uncertainty interval*)ScotlandRisk factors 5 (most deprived)4321 (most affluent)
75534125143.6 (2.5 to 5.0)210Smoking
−141−112−99−75−48−8.2 (−11.1 to −5.9)−475Diabetes
28232116121.7 (1.5 to 2.4)100Physical inactivity
45747946139434036.9 (27.4 to 44.5)2130Systolic blood pressure, mm
Hg†
1701479557438.9 (4.0 to 13.7)510Total cholesterol, mmol/L‡
−53−54−50-44−35−4.1 (−5.6 to −2.4)−235Body mass index
53553546937432538.8 (27.9 to 49.0)2240Total risk factors
54051753847341243.0 (33.0 to 61.3)2480Total treatment§
10751053100684773681.7 (64.7 to 98.8)4720DPPs explained by model
154134385212169—1055DPPS not explained
1230118513901060905—5770Total DPPs
DPPs for Scotland (column 2) and total DPPs (last row) have been rounded to nearest 5.
*95% uncertainty interval corresponds to lower (2.5th centile) and upper (97.5th centile) limits of uncertainty analysis.
†After subtracting DPPs due to hypertension treatment in primary prevention.
‡After subtracting DPPs due to statin treatment in primary prevention.
§See table 2 for detailed breakdown by patient group and treatment type.
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Table 5| Percentage treatment uptake rates for 2000 and 2010 stratified by deprivation fifths
Scottish Index of Multiple Deprivation fifths
Scotland
Treatment by patient group
54321
201020002010200020102000201020002010200020102000
ST elevation myocardial infarction
(2500*):
54.578.757.476.359.475.962.178.060.579.758.577.6Thrombolysis
96.893.896.493.196.193.096.994.697.093.796.693.6Aspirin
74.771.472.169.772.071.471.972.672.975.272.871.7β blocker
80.978.577.075.577.575.977.479.078.479.878.377.5ACE inhibitor or angiotensin
receptor blocker
90.429.289.929.190.328.089.325.890.227.190.028.1Clopidogrel
58.42.656.25.055.84.158.44.066.76.258.64.2Primary percutaneous coronary
intervention
0.00.00.20.00.00.00.00.20.30.00.10.0Primary coronary artery bypass
graft
5.611.15.911.75.511.76.111.45.89.85.811.2CPR in hospital
29.521.526.421.125.325.832.424.227.826.628.323.4CPR in community (1315*)
Non-ST elevation acute coronary
syndrome (9110*):
78.958.080.165.980.167.080.765.679.767.479.964.0Aspirin and heparin
13.128.812.523.412.621.412.223.513.621.412.824.3Aspirin alone
7.04.65.14.85.36.36.07.46.39.65.96.0Platelet glycoprotein IIB/IIIA
inhibitors
75.267.772.864.572.866.272.664.373.368.873.566.2ACE inhibitor or angiotensin
receptor blocker
69.563.966.262.567.164.268.363.568.366.967.963.9β blocker
86.546.486.046.287.143.087.444.787.344.086.845.1Clopidogrel
0.20.40.30.40.50.30.60.40.30.90.40.4Coronary artery bypass graft
surgery
6.42.65.93.36.24.27.83.17.95.66.73.5Percutaneous coronary
intervention
CPR in community
2.45.52.75.52.25.32.24.82.34.52.45.2CPR in hospital (4640*)
Secondary prevention
post-myocardial infarction (60
200*):
83.369.280.969.378.867.378.869.180.067.480.568.6Aspirin
68.643.165.344.064.247.563.345.567.550.965.845.7β blocker
70.224.669.226.764.526.667.129.268.326.468.026.5ACE inhibitor
89.539.887.041.685.740.984.644.284.943.486.641.7Statin
5.74.05.34.26.94.96.05.96.55.36.04.7Warfarin
42.817.342.017.142.117.041.917.041.717.042.117.1Rehabilitation
Secondary prevention
post-revascularisation (40 295):
83.876.878.077.178.570.380.681.475.172.579.275.6Aspirin
65.944.959.739.162.447.161.848.460.348.562.045.3β blocker
60.219.465.324.160.316.353.922.056.921.859.520.7ACE inhibitor
93.461.292.363.890.357.488.562.689.567.390.962.4Statin
5.08.17.79.88.111.27.66.88.36.07.38.5Warfarin
41.342.042.042.541.742.642.442.641.943.141.942.5Rehabilitation (CABG) (7115*)
12.27.512.47.512.37.512.47.512.67.512.47.5Rehabilitation (PCI) (11 100*)
Chronic stable coronary artery
disease (72 395*):
77.260.775.061.272.257.472.060.371.457.773.659.6Aspirin in community
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Table 5 (continued)
Scottish Index of Multiple Deprivation fifths
Scotland
Treatment by patient group
54321
201020002010200020102000201020002010200020102000
78.426.881.728.978.430.276.327.677.631.178.628.7Statins in community
46.414.847.915.741.714.645.115.745.216.845.215.3ACE inhibitor
8.811.49.911.48.610.210.511.911.916.09.811.8CABG surgery (previous 5 years)
Heart failure in hospital (3645*)
65.852.764.751.864.451.562.750.162.650.164.351.4ACE inhibitor
46.732.746.032.245.732.044.431.144.231.045.631.9β blocker
26.521.226.621.226.421.125.420.325.620.526.221.0Spironolactone
82.372.480.172.778.868.677.174.980.770.879.971.9Aspirin
Heart failure in community (16
225):
86.572.779.770.079.361.579.472.579.772.681.469.7ACE inhibitor/or angiotensin
receptor blocker
73.332.165.528.266.932.860.028.257.334.365.830.9β blocker
7.48.216.46.512.76.614.510.47.86.211.77.7Spironolactone
77.777.073.777.871.671.276.971.875.471.975.174.3Aspirin
19.914.018.812.917.812.219.312.415.69.418.312.2Hypertension treatment (3 685
545*)
17.03.214.32.615.32.815.82.813.22.215.12.7Hyperlipidaemia treatment (statins)
(3 685 545*)
Overall treatment uptake rate is weighted average over all age groups ≥25 years and both sexes.
ACE=angiotensin converting enzyme; CABG=coronary artery bypass graft; CPR=cardiopulmonary resuscitation; PCI=percutaneous coronary intervention.
*Number of eligible patients, rounded to nearest 5.
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Table 6| Absolute change in risk factor levels between 2000 and 2010, stratified by deprivation fifths
Change in risk factors
Overall levels*
Risk factor
Scottish Index of Multiple Deprivation fifths
Scotland 5 (most deprived)4321 (most affluent)20102000
Smoking prevalence (%):
−5.5−4.9−4.3−3.5−2.8−4.326.030.3Men
−7.0−5.9−5.1−4.0−3.2−5.223.728.9Women
Diabetes prevalence (%):
3.53.33.33.02.23.17.34.2Men
2.62.12.11.31.21.95.33.4Women
Physical inactivity (%):
−7.8−7.3−7.1−7.3−7.5−7.458.966.3Men
−6.5−6.2−6.1−6.2−6.0−6.268.474.6Women
Systolic blood pressure, mm Hg:
−0.8−0.9−1.0−1.0−1.0−0.9132.2133.1Men
−3.2−3.3−3.1−3.1−3.1−3.2126.9130.1Women
Total cholesterol, mmol/L:
−0.4−0.4−0.4−0.4−0.4−0.45.25.6Men
−0.3−0.3−0.3−0.3−0.3−0.35.45.7Women
Body mass index, kg/m2:
0.90.90.90.90.90.928.227.3Men
0.80.90.80.80.80.827.927.1Women
*Scotland average weighted by 2010 population distribution in 10 year age bands.
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